Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Monday that its second quarter revenues increased 45 percent year over year.

For the three months ended June 30, the San Diego-based liquid biopsy firm saw $1.2 million in revenues compared to the $822,238 it brought in during the same quarter last year.

According to the company, revenue growth reflects a shift in commercial efforts toward specific segments of the oncology market where Biocept believes its assays can help the most patients: prostate, breast, and lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.